This inventor holds 24 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent, primarily in Nucleic Acid Chemistry. Top assignees: Roche Diagnostics Gmbh, Roche Molecular Systems, Inc., Boehringer Mannheim Gmbh. Active years: 1989-2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Paderborn, DE (1989 - 2001)
- Osnabruck, DE (1995 - 2001)
- Osnabr{umlaut over (u)}ck, DE (2001)
- Osnabrück, DE (2001 - 2006)
- Osnabrueck, DE (1998 - 2015)
Company Filing History:
8 out of 488 
5 out of 646 
4 out of 1,164 
Years Active: 1989-2015
Areas of Expertise:
Title: **Frank Seela: Innovator in Nucleic Acid Binding Technologies**
Introduction
Frank Seela, based in Osnabrueck, Germany, is a distinguished inventor with a remarkable portfolio that includes 24 patents. His contributions to the field of molecular biology, particularly in the area of nucleic acid binding compounds, have proven invaluable for diagnostics and therapeutic applications.
Latest Patents
Among his latest innovations, Seela has developed a conjugate that features a thiophilic solid phase linked to an oligonucleotide containing a thiooxonucleotide. This groundbreaking work allows for more efficient binding and detection of nucleic acids. Another notable patent involves nucleic acid binding compounds that incorporate pyrazolo[3,4-D]pyrimidine analogues of purin-2,6-diamine, which have significant implications for the determination and analysis of nucleic acids in diagnostic settings.
Career Highlights
Throughout his career, Frank Seela has made substantial contributions while working at prominent companies such as Roche Diagnostics GmbH and Roche Molecular Systems, Inc. His work has led to advancements in diagnostics and has fostered a deeper understanding of nucleic acid interactions.
Collaborations
Seela has collaborated with notable colleagues, including Herbert von der Eltz and Dieter Heindl. These partnerships have strengthened his research efforts and broadened the impact of his inventions in the scientific community.
Conclusion
Frank Seela's dedication to innovation in nucleic acid technologies continues to drive progress in the field. His impressive array of patents reflects his commitment to enhancing diagnostic methods and the understanding of molecular interactions. With ongoing contributions, he remains a significant figure in the world of scientific innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile